Literature DB >> 21232044

Effects of rosiglitazone on the configuration of action potentials and ion currents in canine ventricular cells.

N Szentandrássy1, G Harmati, L Bárándi, J Simkó, B Horváth, J Magyar, T Bányász, I Lorincz, A Szebeni, V Kecskeméti, P P Nánási.   

Abstract

BACKGROUND AND
PURPOSE: In spite of its widespread clinical application, there is little information on the cellular cardiac effects of the antidiabetic drug rosiglitazone in larger experimental animals. In the present study therefore concentration-dependent effects of rosiglitazone on action potential morphology and the underlying ion currents were studied in dog hearts. EXPERIMENTAL APPROACH: Standard microelectrode techniques, conventional whole cell patch clamp and action potential voltage clamp techniques were applied in enzymatically dispersed ventricular cells from dog hearts. KEY
RESULTS: At concentrations ≥10 µM rosiglitazone decreased the amplitude of phase-1 repolarization, reduced the maximum velocity of depolarization and caused depression of the plateau potential. These effects developed rapidly and were readily reversible upon washout. Rosiglitazone suppressed several transmembrane ion currents, concentration-dependently, under conventional voltage clamp conditions and altered their kinetic properties. The EC(50) value for this inhibition was 25.2 ± 2.7 µM for the transient outward K(+) current (I(to)), 72.3 ± 9.3 µM for the rapid delayed rectifier K(+) current (I(Kr)) and 82.5 ± 9.4 µM for the L-type Ca(2+) current (I(Ca) ) with Hill coefficients close to unity. The inward rectifier K(+) current (I(K1)) was not affected by rosiglitazone up to concentrations of 100 µM. Suppression of I(to), I(Kr), and I(Ca) was confirmed also under action potential voltage clamp conditions. CONCLUSIONS AND IMPLICATIONS: Alterations in the densities and kinetic properties of ion currents may carry serious pro-arrhythmic risk in case of overdose with rosiglitazone, especially in patients having multiple cardiovascular risk factors, like elderly diabetic patients.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21232044      PMCID: PMC3101613          DOI: 10.1111/j.1476-5381.2011.01215.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  39 in total

1.  Apico-basal inhomogeneity in distribution of ion channels in canine and human ventricular myocardium.

Authors:  Norbert Szentadrassy; Tamas Banyasz; Tamas Biro; Gergely Szabo; Balazs I Toth; Janos Magyar; Jozsef Lazar; Andras Varro; Laszlo Kovacs; Peter P Nanasi
Journal:  Cardiovasc Res       Date:  2005-03-01       Impact factor: 10.787

2.  Asymmetrical distribution of ion channels in canine and human left-ventricular wall: epicardium versus midmyocardium.

Authors:  Gergely Szabó; Norbert Szentandrássy; Tamás Bíró; Balázs I Tóth; Gabriella Czifra; János Magyar; Tamás Bányász; András Varró; László Kovács; Péter P Nánási
Journal:  Pflugers Arch       Date:  2005-06-11       Impact factor: 3.657

3.  Channel currents during spontaneous action potentials in embryonic chick heart cells. The action potential patch clamp.

Authors:  R Fischmeister; L J DeFelice; R K Ayer; R Levi; R L DeHaan
Journal:  Biophys J       Date:  1984-08       Impact factor: 4.033

4.  Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes.

Authors:  G A Knock; S K Mishra; P I Aaronson
Journal:  Eur J Pharmacol       Date:  1999-02-26       Impact factor: 4.432

5.  Troglitazone inhibits voltage-dependent calcium currents in guinea pig cardiac myocytes.

Authors:  T Nakajima; K Iwasawa; H Oonuma; H Imuta; H Hazama; M Asano; T Morita; F Nakamura; J Suzuki; S Suzuki; Y Kawakami; M Omata; Y Okuda
Journal:  Circulation       Date:  1999-06-08       Impact factor: 29.690

6.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches.

Authors:  O P Hamill; A Marty; E Neher; B Sakmann; F J Sigworth
Journal:  Pflugers Arch       Date:  1981-08       Impact factor: 3.657

7.  Vmax as a measure of GNa in nerve and cardiac membranes.

Authors:  G Strichartz; I Cohen
Journal:  Biophys J       Date:  1978-07       Impact factor: 4.033

8.  Effects of troglitazone and pioglitazone on the action potentials and membrane currents of rabbit ventricular myocytes.

Authors:  S Ikeda; T Watanabe
Journal:  Eur J Pharmacol       Date:  1998-09-18       Impact factor: 4.432

9.  Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice.

Authors:  J Berger; P Bailey; C Biswas; C A Cullinan; T W Doebber; N S Hayes; R Saperstein; R G Smith; M D Leibowitz
Journal:  Endocrinology       Date:  1996-10       Impact factor: 4.736

10.  Action potentials and potassium currents in rat ventricular muscle during experimental diabetes.

Authors:  J Magyar; Z Rusznák; P Szentesi; G Szûcs; L Kovács
Journal:  J Mol Cell Cardiol       Date:  1992-08       Impact factor: 5.000

View more
  8 in total

1.  Cardiac ion channel modulation by the hypoglycaemic agent rosiglitazone.

Authors:  J C Hancox
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

Review 2.  Minireview: Challenges and opportunities in development of PPAR agonists.

Authors:  Matthew B Wright; Michele Bortolini; Moh Tadayyon; Martin Bopst
Journal:  Mol Endocrinol       Date:  2014-08-22

3.  Chemical proteomics-based analysis of off-target binding profiles for rosiglitazone and pioglitazone: clues for assessing potential for cardiotoxicity.

Authors:  Brian R Hoffmann; Mohamed F El-Mansy; Daniel S Sem; Andrew S Greene
Journal:  J Med Chem       Date:  2012-09-28       Impact factor: 7.446

Review 4.  PPAR-γ as a therapeutic target in cardiovascular disease: evidence and uncertainty.

Authors:  Janice V Huang; Clifford R Greyson; Gregory G Schwartz
Journal:  J Lipid Res       Date:  2012-06-08       Impact factor: 5.922

5.  Computational Identification of Novel Kir6 Channel Inhibitors.

Authors:  Xingyu Chen; Arthur Garon; Marcus Wieder; Marien J C Houtman; Eva-Maria Zangerl-Plessl; Thierry Langer; Marcel A G van der Heyden; Anna Stary-Weinzinger
Journal:  Front Pharmacol       Date:  2019-05-24       Impact factor: 5.988

Review 6.  Drug-induced mitochondrial dysfunction and cardiotoxicity.

Authors:  Zoltán V Varga; Peter Ferdinandy; Lucas Liaudet; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-09-18       Impact factor: 4.733

7.  Role of action potential configuration and the contribution of C²⁺a and K⁺ currents to isoprenaline-induced changes in canine ventricular cells.

Authors:  N Szentandrássy; V Farkas; L Bárándi; B Hegyi; F Ruzsnavszky; B Horváth; T Bányász; J Magyar; I Márton; P P Nánási
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

8.  Experimentally-Based Computational Investigation into Beat-To-Beat Variability in Ventricular Repolarization and Its Response to Ionic Current Inhibition.

Authors:  E Pueyo; C E Dangerfield; O J Britton; L Virág; K Kistamás; N Szentandrássy; N Jost; A Varró; P P Nánási; K Burrage; B Rodríguez
Journal:  PLoS One       Date:  2016-03-28       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.